新型生物瓣主动脉瓣置换术后抗血栓治疗与出血事件:PERIGON试验分析
基于PERIGON关键试验1115例Avalus瓣主动脉瓣置换患者,分析术后3年内出血与血栓栓塞事件。3年全因死亡Kaplan-Meier累积概率为7.2%,全部出血和主要出血累积概率分别为8.7%和5.2%。多数出血发生在术后30天以后,且患者多因非术后预防指征使用抗血小板/抗凝药物。
要点
- 3年全因死亡累积概率7.2%,主要出血累积概率5.2%。
- 晚期出血相关因素包括年龄、外周血管病、肾功能不全和抗血栓药物使用。
核心结论
- 总体临床结局显示低死亡率和少量并发症,但主要出血仍值得关注。
- 多数出血事件发生于术后30天以后,且患者多因非术后预防指征使用抗血小板和/或抗凝药物。
研究设计与样本
- PERIGON关键试验分析,1115例患者接受Avalus瓣主动脉瓣置换,分析术后3年内出血和血栓栓塞事件的频率、时机和严重程度。
主要发现
- 3年全因死亡Kaplan-Meier累积概率为7.2%(心脏性3.6%;瓣膜相关1.1%)。
- 全部出血和主要出血的Kaplan-Meier累积概率分别为8.7%和5.2%。
- 51例晚期主要出血中,5例事件发生时因术后预防使用抗凝/抗血小板药物,其余因其他原因用药。
- 晚期出血(主要和次要)相关因素:年龄(HR 1.035;95%CI 1.004-1.068)、外周血管病(HR 2.135;95%CI 1.106-4.122)、肾功能不全(HR 1.920;95%CI 1.055-3.494)、事件时抗血栓药物使用(HR 1.417;95%CI 1.048-1.915)。
临床怎么用
- 术后30天以后仍需关注出血风险,尤其对高龄、外周血管病、肾功能不全及使用抗血栓药物的患者。
- 应评估抗血小板/抗凝药物的使用指征,非术后预防指征的用药可能与晚期出血相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Several recent-generation surgical tissue valves have been found to have bleeding rates exceeding rates recommended by regulatory bodies. We explored bleeding events using data from the Pericardial Surgical Aortic Valve Replacement (PERIGON) Pivotal Trial for the Avalus valve (Medtronic, Minneapolis, Minn) to examine whether this end point remains relevant for the evaluation of bioprostheses. METHODS: Patients (n = 1115) underwent aortic valve replacement. Bleeding and thromboembolic event episodes in patients within 3 years postimplant were analyzed for frequency, timing, and severity, focusing on patients taking antiplatelet/anticoagulant medications at the time of the event. Clinical and hemodynamic outcomes are also reported. RESULTS: At 3 years, the Kaplan-Meier cumulative probability estimate of all-cause death was 7.2% (cardiac, 3.6%; valve-related, 1.1%). The Kaplan-Meier cumulative probability estimates of all and major hemorrhage were 8.7% and 5.2%, respectively. Ninety-nine bleeding events occurred in 86 patients: most occurred >30 days postsurgery. Among the 51 late major bleeds, in 5 cases the patients were taking anticoagulant/antiplatelet medication for prophylaxis after surgical aortic valve replacement at the time of the event, whereas the remaining patients were taking medications for other reasons. Age (hazard ratio, 1.035; 95% confidence interval, 1.004-1.068), peripheral vascular disease (hazard ratio, 2.135; 95% confidence interval, 1.106-4.122), renal dysfunction (hazard ratio, 1.920; 95% confidence interval, 1.055-3.494), and antithrombotic medication use at the time of the event (hazard ratio, 1.417; 95% confidence interval, 1.048-1.915) were associated with late bleeds (major and minor). CONCLUSIONS: Overall clinical outcomes demonstrated low mortality and few complications except for major bleeding. Most bleeding events occurred >30 days after surgery and in patients taking antiplatelet and/or anticoagulation for indications other than postimplant prophylaxis.
引用
- Klautz RJM, Vriesendorp MD, Dagenais F, et al. Antithrombotic therapy and bleeding events after aortic valve replacement with a novel bioprosthesis. J Thorac Cardiovasc Surg. 2019. PMID: 31864696. doi:10.1016/j.jtcvs.2019.10.095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。